BR0209155A - Tablete farmacêutico tendo um teor de api elevado - Google Patents
Tablete farmacêutico tendo um teor de api elevadoInfo
- Publication number
- BR0209155A BR0209155A BR0209155-0A BR0209155A BR0209155A BR 0209155 A BR0209155 A BR 0209155A BR 0209155 A BR0209155 A BR 0209155A BR 0209155 A BR0209155 A BR 0209155A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical tablet
- api content
- high api
- tablet
- content
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
"TABLETE FARMACêUTICO TENDO UM TEOR DE API ELEVADO". A invenção refere-se a um tablete contendo um percentual notavelmente elevado de um ingrediente ativo em proporções para excipientes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28668201P | 2001-04-26 | 2001-04-26 | |
US28687001P | 2001-04-26 | 2001-04-26 | |
PCT/US2002/012915 WO2002087548A1 (en) | 2001-04-26 | 2002-04-23 | A pharmaceutical tablet having a high api content |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0209155A true BR0209155A (pt) | 2004-10-05 |
Family
ID=26964005
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0209199-2A BR0209199A (pt) | 2001-04-26 | 2002-04-23 | Controle de campactabilidade através de cristalização |
BR0209155-0A BR0209155A (pt) | 2001-04-26 | 2002-04-23 | Tablete farmacêutico tendo um teor de api elevado |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0209199-2A BR0209199A (pt) | 2001-04-26 | 2002-04-23 | Controle de campactabilidade através de cristalização |
Country Status (13)
Country | Link |
---|---|
US (2) | US20040175419A1 (pt) |
EP (2) | EP1390011A2 (pt) |
JP (2) | JP2005505501A (pt) |
KR (1) | KR20040036686A (pt) |
CN (2) | CN1523981A (pt) |
BR (2) | BR0209199A (pt) |
CA (2) | CA2445702A1 (pt) |
CZ (2) | CZ20032901A3 (pt) |
HU (2) | HUP0400377A2 (pt) |
IL (2) | IL158235A0 (pt) |
MX (2) | MXPA03009676A (pt) |
PL (2) | PL367262A1 (pt) |
WO (2) | WO2002087548A1 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2262567T3 (es) | 2001-03-20 | 2006-12-01 | Schwarz Pharma Ag | Nuevo uso de una clase peptidica de compuesto para tratamiento del dolor inflamatorio no neuropatico. |
DE60100055T2 (de) | 2001-03-21 | 2003-07-24 | Sanol Arznei Schwarz Gmbh | Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen |
US20080182801A1 (en) | 2003-12-22 | 2008-07-31 | Btg International Limited | Core 2 glcnac-t inhibitors |
GB0513881D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors III |
GB0329667D0 (en) | 2003-12-22 | 2004-01-28 | King S College London | Core 2 GlcNAc-T inhibitor |
EP1604656A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS) |
CA2573125A1 (en) | 2004-08-27 | 2006-03-02 | Schwarz Pharma Ag | Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain |
GB0513883D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Diagnosis of Atherosclerosis |
GB0513888D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors II |
EA019757B1 (ru) | 2006-06-15 | 2014-06-30 | ЮСиБи ФАРМА ГМБХ | Фармацевтическая композиция с синергетическим противосудорожным эффектом |
GB0722484D0 (en) * | 2007-11-15 | 2007-12-27 | Ucl Business Plc | Solid compositions |
EP2576592A1 (en) | 2010-06-07 | 2013-04-10 | Telik, Inc. | Preparation of crystalline ezatiostat hydrochloride ansolvate form d |
CA2797458A1 (en) * | 2010-06-07 | 2011-12-15 | Telik, Inc. | Tablet formulation of ezatiostat |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4476248A (en) * | 1983-02-28 | 1984-10-09 | The Upjohn Company | Crystallization of ibuprofen |
BR9206996A (pt) * | 1991-12-30 | 1995-12-05 | Fmc Corp | Composição adequada para preparar esferóides por esferoidização processo para produzir um material em partículas processo para produzir uma forma de dosagem de sólido esferoidizado em partículas e forma de dosagem sólida |
HUP0003760A3 (en) * | 1995-10-05 | 2001-05-28 | Darwin Discovery Ltd Cambridge | Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation, process for production thereof and their use |
-
2002
- 2002-04-23 US US10/475,959 patent/US20040175419A1/en not_active Abandoned
- 2002-04-23 CN CNA028089944A patent/CN1523981A/zh active Pending
- 2002-04-23 IL IL15823502A patent/IL158235A0/xx unknown
- 2002-04-23 CZ CZ20032901A patent/CZ20032901A3/cs unknown
- 2002-04-23 KR KR10-2003-7013698A patent/KR20040036686A/ko not_active Application Discontinuation
- 2002-04-23 WO PCT/US2002/012915 patent/WO2002087548A1/en not_active Application Discontinuation
- 2002-04-23 MX MXPA03009676A patent/MXPA03009676A/es unknown
- 2002-04-23 BR BR0209199-2A patent/BR0209199A/pt unknown
- 2002-04-23 BR BR0209155-0A patent/BR0209155A/pt not_active Application Discontinuation
- 2002-04-23 EP EP02728982A patent/EP1390011A2/en not_active Withdrawn
- 2002-04-23 IL IL15841202A patent/IL158412A0/xx unknown
- 2002-04-23 HU HU0400377A patent/HUP0400377A2/hu unknown
- 2002-04-23 MX MXPA03009689A patent/MXPA03009689A/es unknown
- 2002-04-23 JP JP2002585919A patent/JP2005505501A/ja active Pending
- 2002-04-23 US US10/476,047 patent/US20040208924A1/en not_active Abandoned
- 2002-04-23 PL PL02367262A patent/PL367262A1/xx not_active Application Discontinuation
- 2002-04-23 PL PL02373548A patent/PL373548A1/xx not_active Application Discontinuation
- 2002-04-23 WO PCT/US2002/013055 patent/WO2002088664A2/en not_active Application Discontinuation
- 2002-04-23 CA CA002445702A patent/CA2445702A1/en not_active Abandoned
- 2002-04-23 EP EP02723952A patent/EP1390018A1/en not_active Withdrawn
- 2002-04-23 JP JP2002584894A patent/JP2004530679A/ja not_active Withdrawn
- 2002-04-23 CN CNA02812779XA patent/CN1520283A/zh active Pending
- 2002-04-23 CZ CZ20032902A patent/CZ20032902A3/cs unknown
- 2002-04-23 HU HU0303860A patent/HUP0303860A3/hu unknown
- 2002-04-23 CA CA002445290A patent/CA2445290A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20040175419A1 (en) | 2004-09-09 |
HUP0400377A2 (en) | 2007-09-28 |
JP2005505501A (ja) | 2005-02-24 |
HUP0303860A3 (en) | 2005-05-30 |
WO2002088664A3 (en) | 2003-08-21 |
CN1523981A (zh) | 2004-08-25 |
JP2004530679A (ja) | 2004-10-07 |
IL158412A0 (en) | 2004-05-12 |
MXPA03009676A (es) | 2004-02-12 |
EP1390011A2 (en) | 2004-02-25 |
BR0209199A (pt) | 2006-02-07 |
MXPA03009689A (es) | 2004-02-12 |
HUP0303860A2 (hu) | 2004-03-29 |
WO2002087548A1 (en) | 2002-11-07 |
CZ20032901A3 (en) | 2004-07-14 |
US20040208924A1 (en) | 2004-10-21 |
KR20040036686A (ko) | 2004-04-30 |
CZ20032902A3 (cs) | 2004-01-14 |
CN1520283A (zh) | 2004-08-11 |
IL158235A0 (en) | 2004-05-12 |
PL373548A1 (en) | 2005-09-05 |
PL367262A1 (en) | 2005-02-21 |
CA2445702A1 (en) | 2002-11-07 |
CA2445290A1 (en) | 2002-11-07 |
EP1390018A1 (en) | 2004-02-25 |
WO2002088664A2 (en) | 2002-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE293995T1 (de) | Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten | |
BR0003158A (pt) | Formulação de dosagem oral de derretimentoinstantâneo | |
PT1412384E (pt) | Formulação estável de glp-1 modificado | |
BR0209155A (pt) | Tablete farmacêutico tendo um teor de api elevado | |
ECSP045102A (es) | Formulación farmacéutica que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol y proporciona una liberación retardada del ingrediente activo | |
BR0210139A (pt) | Composições farmacêuticas | |
SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
TR200401793T4 (tr) | Perindopril tuzu ve bunu içeren farmasötik bileşimler. | |
CY1107819T1 (el) | Φαρμακευτικη διαμορφωση της ολανζαπινης | |
MY129668A (en) | Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes | |
BR0209283A (pt) | Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme | |
NO20034863L (no) | Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser | |
AR011919A1 (es) | FORMULACIoN EN COMPRIMIDOS O CÁPSULAS PARA TRAGAR DE PARACETAMOL (N-ACETIL-P-AMINOFENOL) Y PROCEDIMIENTO PARA PREPARARLA | |
EE200100104A (et) | 5-HT4 agonisti või antagonisti uus peroraalne ravimvorm | |
BR0306928A (pt) | Composições farmacêuticas estáveis compreendendo inibidores de enzimas conversoras de angiotensina (ace) | |
MXPA03010054A (es) | Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos. | |
RS53804A (en) | Parenteral composition of paracetamol | |
MY141012A (en) | Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser | |
MXPA03011317A (es) | Comprimido masticable que comprende paracetamol. | |
CY1107295T1 (el) | Σταθεροποιηση στερεων φορμουλων φαρμακων του θυρεοειδους | |
MXPA04001252A (es) | Nuevos heterociclos benzo-fusionados como antagonistas de endotelina. | |
BR0206819A (pt) | Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca | |
MXPA03010672A (es) | Composicion para el tratamiento regenerativo de enfermedades del cartilago. | |
WO2003028624A3 (en) | Levothyroxine compositions and methods | |
PT1178787E (pt) | Composicoes farmacologicas para administracao por via oral de floroglucinol e suas preparacoes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |